BioNTech SE (BNTX) Notes Payables (2019 - 2025)

BioNTech SE has disclosed Notes Payables across 7 years of filings, most recently posting $45.0 million for Q3 2025.

• Notes Payables for Q3 2025 came in at $45.0 million, changed N/A year-over-year; the trailing twelve-month figure through Sep 2025 was $45.0 million (changed N/A YoY), and the FY2023 annual result was $2.5 million, up 15.5% from the prior year.
• Notes Payables came in at $45.0 million for Q3 2025 at BioNTech SE, up from $44.7 million in the prior quarter.
• In the past five years, Notes Payables ranged from a high of $285.4 million in Q1 2021 to a low of $2.1 million in Q4 2022.
• The 5-year median for Notes Payables is $46.8 million (2025), against an average of $105.3 million.
• Across the five-year window, Notes Payables slumped 98.91% in 2022 and soared 1844.95% in 2025, its largest moves.
• BioNTech SE's Notes Payables stood at $196.3 million in 2021, then slumped by 98.91% to $2.1 million in 2022, then gained by 15.5% to $2.5 million in 2023, then increased by 0.97% to $2.5 million in 2024, then soared by 1701.33% to $45.0 million in 2025.
• The last three Notes Payables figures came in at $45.0 million (Q3 2025), $44.7 million (Q2 2025), and $48.6 million (Q1 2025), per Business Quant data.